Prelude Therapeutics Incorporated (PRLD)

Market Cap	262.27M
Revenue (ttm)	n/a
Net Income (ttm)	-121.83M
Shares Out	67.77M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,853
Open	3.890
Previous Close	3.850
Day's Range	3.870 - 4.070
52-Week Range	1.660 - 6.890
Beta	1.50
Analysts	Hold
Price Target	5.25 (+35.66%)
Earnings Date	May 7, 2024

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: PRLD

Analyst Forecast

According to 4 analysts, the average rating for PRLD stock is "Hold." The 12-month stock price forecast is $5.25, which is an increase of 35.66% from the latest price.

Price Target

$5.25

(35.66% upside)

Analyst Consensus: Hold